"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.
"In a disease characterized by unrelenting decline, the results depict the long-term clinical stability afforded by TTR reduction and the long-term safety of patisiran treatment."
A prefilled syringe version of VYVGART Hytrulo, which enables adult patients with generalized myasthenia gravis or chronic inflammatory demyelinating polyneuropathy to self-administer treatment in as little as 20 to 30 seconds, has been approved by the FDA.
Elevated risk scores are significantly associated with an increased likelihood of seizure recurrence, according to a recent study on pediatric epilepsy.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Findings suggest that nicotine intake is similar among adolescents who vape and adolescents who smoke, highlighting critical implications for addiction.
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.